Tony Traboulsee, MD (Neurology) University of British Columbia CMSC June 5th, 2004 Toronto, Ontario Defining suboptimal response to MS treatment: MRI outcome.
CARS Benzimidazole Resistance Workgroup Update 2009 Philip J. Skuce, Moredun Research Institute, Edinburgh, UK.
Introduction Eugene R. Schiff, MD
Preoperative Use of Parenteral Iron
splenic embo.ppt
Ash 2014 update
Shivag june 2015 law_finalcopy2
+ Roles of Laparoscopic Sleeve Gastrectomy in Bariatric Surgery Vincent Lau TKOH.
Perspectives on Best Practices for Managing Acute Relapses in Multiple Sclerosis Moderator Barry G. Arnason, MD Professor of Neurology University of Chicago.
Elias Jabbour, MD University of Texas – M. D. Anderson Cancer Center CML and Imatinib Resistance: Which TKI and When?
ABAM/CNHF Project FELLOWSHIPS FELLOWS TRAINING EVENTS.
Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (Pts) with Durably Undetectable BCR-ABL Transcripts:
